相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease
Matthias Jurgens et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Serum Lipopolysaccharide-binding Protein and Soluble CD14 Are Markers of Disease Activity in Patients with Crohn's Disease
Peter Laszlo Lakatos et al.
INFLAMMATORY BOWEL DISEASES (2011)
The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy
S. Lichtiger et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease
R. Panaccione et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis
Tamas Szamosi et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2010)
W1275 Long-Term Durability of Response to Adalimumab Treatment in Crohn's Disease
Maria Chaparro et al.
GASTROENTEROLOGY (2010)
Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease
Filip Baert et al.
GASTROENTEROLOGY (2010)
Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy
Harry Sokol et al.
GUT (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Is the disease course predictable in inflammatory bowel diseases?
Peter Laszlo Lakatos et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience
A. Oussalah et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
F. Schnitzler et al.
GUT (2009)
Adalimumab for the treatment of fistulas in patients with Crohn's disease
J-F Colombel et al.
GUT (2009)
Mucosal Healing Predicts Long-term Outcome of Maintenance Therapy with Infliximab in Crohn's Disease
Fabian Schnitzler et al.
INFLAMMATORY BOWEL DISEASES (2009)
P033 - Risk of Crohn's disease-related hospitalization in patients receiving long-term adalimumab therapy: 3-year data from CHARM and ADHERE
E.V. Loftus et al.
Journal of Crohns & Colitis (2009)
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a Randomized trial
Gert Van Assche et al.
GASTROENTEROLOGY (2008)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial
William J. Sandborn et al.
ANNALS OF INTERNAL MEDICINE (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
European evidence based consensus on the diagnosis and management of Crohn's disease:: definitions and diagnosis
EF Stange et al.
GUT (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease
S Schreiber et al.
GASTROENTEROLOGY (2005)
Infliximab in the treatment of Crohn's disease: Predictors of response in an Italian multicentric open study
A Orlando et al.
DIGESTIVE AND LIVER DISEASE (2005)
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Mark S. Silverberg et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2005)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease
DS Fefferman et al.
INFLAMMATORY BOWEL DISEASES (2004)
An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease
IDR Arnott et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Predictors of response to infliximab in patients with Crohn's disease
MA Parsi et al.
GASTROENTEROLOGY (2002)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
分享论文
